Nektar Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

14.03.22	Bristol Myers Squibb, Nektar Say Phase 3 PIVOT IO-001 Trial Fails To Meet Endpoints (RTTNews)
14.03.22	Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors Following Announcement of Update from Bristol-Myers Squibb and Nektar on the PIVOT-IO-001 Phase 3 Trial (PR Newswire)
28.02.22	Nektar Therapeutics Q4 Loss increases, but beats estimates (RTTNews)
28.02.22	Nektar Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results (PR Newswire)
27.02.22	Ausblick: Nektar Therapeutics zieht Bilanz zum abgelaufenen Quartal (finanzen.net)
18.02.22	Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2021 on Monday, February 28, 2022, After Close of U.S.-Based Financial Markets (PR Newswire)
05.01.22	Nektar Therapeutics' President and CEO, Howard Robin, to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference (PR Newswire)
15.12.21	Nektar Announces Positive Phase 1b Data For NKTR-358 In Patients With Atopic Dermatitis (RTTNews)
15.12.21	Nektar Therapeutics Announces Phase 1b Data for Novel T Regulatory Cell Stimulator NKTR-358 (LY3471851) in Patients with Atopic Dermatitis (PR Newswire)
13.12.21	Nektar Therapeutics Presents Clinical Data for NKTR-255 in Patients with Relapsed/Refractory Hematologic Malignancies, Including Patients with Prior CAR-T Therapy, at the 63rd American Society of ... (PR Newswire)
04.12.21	Signature Bank, SolarEdge Technologies and FactSet Research Systems Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 (PR Newswire)
30.11.21	Nektar Therapeutics Announces Data Presentations for its Immuno-Oncology Programs at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2021 and the 63rd American Society... (PR Newswire)
15.11.21	Nektar Therapeutics Strengthens Board of Directors with Appointment of Diana M. Brainard, M.D. (PR Newswire)
12.11.21	Nektar Therapeutics Announces Data Presentations for Its Immuno-Oncology Pipeline at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting (PR Newswire)
09.11.21	Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors with Cancer Specialist During 2021 Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting (PR Newswire)
04.11.21	Nektar Therapeutics Q3 Earnings Summary (RTTNews)
04.11.21	Nektar Therapeutics Reports Third Quarter 2021 Financial Results (PR Newswire)
03.11.21	Ausblick: Nektar Therapeutics informiert über die jüngsten Quartalsergebnisse (finanzen.net)
27.10.21	Nektar to Announce Financial Results for the Third Quarter 2021 on Thursday, November 4, 2021, After Close of U.S.-Based Financial Markets (PR Newswire)
21.09.21	Nektar Collaborates With Merck KGaA, Pfizer To Evaluate NKTR-255 In Combination With Avelumab (RTTNews)
21.09.21	Nektar Announces New Clinical Collaboration with Merck KGaA Darmstadt, Germany and Pfizer Inc. to Combine NKTR-255, a Novel Interleukin-15 Agonist, with Avelumab in the JAVELIN Bladder Medley Study (PR Newswire)
05.08.21	EARNINGS SUMMARY: Details of Nektar Therapeutics Q2 Earnings Report (RTTNews)
05.08.21	Nektar Therapeutics Reports Second Quarter 2021 Financial Results (PR Newswire)
03.08.21	Ausblick: Nektar Therapeutics gibt Ergebnis zum abgelaufenen Quartal bekannt (finanzen.net)
28.07.21	Nektar to Announce Financial Results for the Second Quarter 2021 on Thursday, August 5, 2021, After Close of U.S.-Based Financial Markets (PR Newswire)
19.07.21	Nektar Appoints Dimitry S.A. Nuyten, M.D., Ph.D., as Senior Vice President and Chief Medical Officer (PR Newswire)
14.06.21	Exelixis, Bristol Myers To Evaluate XL092-Immuno-oncology Therapies In Advanced Solid Tumors (RTTNews)
06.05.21	EARNINGS SUMMARY: Details of Nektar Therapeutics Q1 Earnings Report (RTTNews)
23.03.21	Ionis Pharmaceuticals Helps Lead The Biotechnology Sector Lower (RTTNews)
25.02.21	EARNINGS SUMMARY: Details of Nektar Therapeutics Q4 Earnings Report (RTTNews)
23.02.21	Ausblick: Nektar Therapeutics stellt Zahlen zum jüngsten Quartal vor (finanzen.net)
18.02.21	NKTR Teams Up With MRK, Pfizer Initiates Multiple Myeloma Trial, PCSA On Watch (RTTNews)
17.02.21	Nektar Collaborates With SFJ Pharma For Bempegaldesleukin In Head And Neck Cancer (RTTNews)
08.11.20	Week Ahead In Pharma: FDA Decisions, SITC Presentations, 13D SEC Filing (RTTNews)
05.11.20	EARNINGS SUMMARY: Details of Nektar Therapeutics Q3 Earnings Report (RTTNews)
06.08.20	EARNINGS SUMMARY: Details of Nektar Therapeutics Q2 Earnings Report (RTTNews)
05.08.20	Ausblick: Nektar Therapeutics verkündet Quartalsergebnis zum jüngsten Jahresviertel (finanzen.net)
31.05.20	Analysten sehen bei Nektar Therapeutics-Aktie Potenzial (finanzen.net)
07.05.20	EARNINGS SUMMARY: Details of Nektar Therapeutics Q1 Earnings Report (RTTNews)
07.05.20	Ausblick: Nektar Therapeutics öffnet die Bücher zum abgelaufenen Quartal (finanzen.net)
31.03.20	So schätzen Analysten die Nektar Therapeutics-Aktie ein (finanzen.net)
27.02.20	Nektar Therapeutics Posts Wider Loss In Q4 - Quick Facts (RTTNews)
27.02.20	EARNINGS SUMMARY: Details of Nektar Therapeutics Q4 Earnings Report (RTTNews)
26.02.20	Ausblick: Nektar Therapeutics informiert über die jüngsten Quartalsergebnisse (finanzen.net)
03.02.20	Nektar Publishes Two Manuscripts On Its Immuno-oncology Candidate, Bempeg (RTTNews)
16.01.20	KALA Strides, NKTR Plunges, RMTI In Deal With Sun Pharma, DRRX Faces FDA Panel (RTTNews)
15.01.20	Nektar To Withdraw NDA For Oxycodegol (RTTNews)
31.12.19	Biotech Stocks Facing FDA Decision In January 2020 (RTTNews)
20.11.19	ÜBERBLICK/Anstehende Indexänderungen (Dow Jones)
11.11.19	LPCN Awaits FDA Word, NKTR On Track, All's Well With Five Prime's FPT155 (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

04.12.24		Freundlicher Handel: NASDAQ Composite am Mittag im Plus
03.12.24		Aufschläge in New York: NASDAQ Composite beendet den Handel mit Gewinnen
27.11.24		Handel in New York: NASDAQ Composite verbucht am Mittwochnachmittag Abschläge
22.11.24		Börse New York: NASDAQ Composite stärker
22.11.24		Starker Wochentag in New York: Zum Handelsstart Gewinne im NASDAQ Composite
15.11.24		Schwacher Handel in New York: NASDAQ Composite verbucht zum Handelsende Abschläge
15.11.24		Zurückhaltung in New York: NASDAQ Composite verbucht nachmittags Verluste
15.11.24		NASDAQ Composite aktuell: NASDAQ Composite mittags mit Abgaben

04.12.24

Freundlicher Handel: NASDAQ Composite am Mittag im Plus

03.12.24

Aufschläge in New York: NASDAQ Composite beendet den Handel mit Gewinnen

27.11.24

Handel in New York: NASDAQ Composite verbucht am Mittwochnachmittag Abschläge

22.11.24

Börse New York: NASDAQ Composite stärker

22.11.24

Starker Wochentag in New York: Zum Handelsstart Gewinne im NASDAQ Composite

15.11.24

Schwacher Handel in New York: NASDAQ Composite verbucht zum Handelsende Abschläge

15.11.24

Zurückhaltung in New York: NASDAQ Composite verbucht nachmittags Verluste

15.11.24

NASDAQ Composite aktuell: NASDAQ Composite mittags mit Abgaben

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Lonza Grp	550.80	5.44 %	K V
CieFinRichemont	135.60	1.46 %	K V
UBS Group	28.63	1.17 %	K V
Holcim	90.24	1.14 %	K V
Alcon	76.36	0.37 %	K V
Part Grp Hldg	1’294.00	-0.23 %	K V
Roche Hldg G	255.20	-0.27 %	K V
Sika	231.10	-0.39 %	K V
Swiss Life Hldg	687.40	-0.64 %	K V
Kuehne+Nagel Int	204.20	-3.18 %	K V

Nachrichten zu Nektar Therapeutics

Aktien Top/Flop

Nektar Therapeutics Peer Group Nachrichten

Meistgelesene Nachrichten